Company Filing History:
Years Active: 2023
Title: Callum M Sloss: Innovator in Therapeutic Combinations
Introduction
Callum M Sloss is a notable inventor based in Wakefield, MA (US). He has made significant contributions to the field of immunotherapy, particularly in the treatment of hematological malignancies. His innovative work focuses on therapeutic combinations that enhance clinical efficacy while reducing toxicity.
Latest Patents
Callum M Sloss holds a patent for "Therapeutic combinations comprising anti-CD123 immunoconjugates." This patent details therapeutic combinations of immunoconjugates that bind to CD123, such as IMGN632, with BCL-2 inhibitors like venetoclax and/or hypomethylating agents such as azacitidine or decitabine. The patent also outlines methods for administering these combinations to treat hematological malignancies effectively. Additionally, it provides methods for treating hematological malignancies that present as minimal residual disease using immunoconjugates that bind to CD123.
Career Highlights
Callum is currently associated with Immunogen, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing quest to improve treatment options for patients suffering from blood cancers.
Collaborations
He collaborates with esteemed colleagues, including Sharlene Adams and Patrick Zweidler-McKay, to further enhance the impact of his research in the field of immunotherapy.
Conclusion
Callum M Sloss is a dedicated inventor whose work in therapeutic combinations is paving the way for more effective treatments for hematological malignancies. His contributions are vital to the advancement of cancer therapies, showcasing the importance of innovation in medicine.